{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T02:18:51Z","timestamp":1789957131755,"version":"4.0.1"},"reference-count":104,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","croh-online.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.critrevonc.2015.01.002","type":"journal-article","created":{"date-parts":[[2015,1,12]],"date-time":"2015-01-12T02:35:53Z","timestamp":1421030153000},"page":"1-10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":185,"special_numbering":"C","title":["Recent developments in l-asparaginase discovery and its potential as anticancer agent"],"prefix":"10.1016","volume":"100","author":[{"given":"Abhinav","family":"Shrivastava","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul Arif","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsin","family":"Khurshid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohd Abul","family":"Kalam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhir K.","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradeep K.","family":"Singhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.critrevonc.2015.01.002_bib0940","first-page":"617","article-title":"Antitumor activity and other biologic properties of L-asparaginase (NSC-109229) \u2013 a review","volume":"52","author":"Adamson","year":"1968","journal-title":"Cancer Chemother Rep"},{"issue":"4","key":"10.1016\/j.critrevonc.2015.01.002_bib0675","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1046\/j.1365-2141.1997.d01-2089.x","article-title":"Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemia","volume":"96","author":"Ahlke","year":"1997","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.critrevonc.2015.01.002_bib0700","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s002800100286","article-title":"Pharmacokinetics of Erwinia asparaginase after intravenous and intramuscular administration","volume":"48","author":"Albertsen","year":"2001","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"10.1016\/j.critrevonc.2015.01.002_bib0720","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1046\/j.0306-5251.2001.01464.x","article-title":"Monitoring of Erwinia asparaginase therapy in childhood ALL in the Nordic countries","volume":"52","author":"Albertsen","year":"2001","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.critrevonc.2015.01.002_bib0725","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/mpo.10096","article-title":"Antibody formation during intravenous and intramuscular therapy with Erwinia asparaginase","volume":"38","author":"Albertsen","year":"2002","journal-title":"Med Pediatr Oncol"},{"issue":"1","key":"10.1016\/j.critrevonc.2015.01.002_bib1005","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/BF02867729","article-title":"Antineoplastic activity in L-asparaginase of Cladosporium cladosporiodies","volume":"8","author":"Ali","year":"1993","journal-title":"Ind J Clin Biochem"},{"issue":"11","key":"10.1016\/j.critrevonc.2015.01.002_bib0780","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1038\/sj.leu.2403143","article-title":"Lack of asparagine depletion in the cerebrospinal fluid after one intravenous dose of PEG-asparaginase: a window study at initial diagnosis of childhood ALL","volume":"17","author":"Appel","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2015.01.002_bib1000","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1080\/00021369.1972.10860270","article-title":"Production of extracellular L-asparaginases by microorganisms","volume":"36","author":"Arima","year":"1972","journal-title":"Agri Biol Chem"},{"issue":"1","key":"10.1016\/j.critrevonc.2015.01.002_bib0800","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/cncr.22739","article-title":"Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients","volume":"110","author":"Armstrong","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2015.01.002_bib0810","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/978-1-4615-4811-9_69","article-title":"The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia","volume":"457","author":"Asselin","year":"1999","journal-title":"Adv Exp Med Biol"},{"issue":"9","key":"10.1016\/j.critrevonc.2015.01.002_bib0685","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1200\/JCO.1993.11.9.1780","article-title":"Comparative pharmacokinetic studies of three asparaginase preparations","volume":"11","author":"Asselin","year":"1993","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.critrevonc.2015.01.002_bib1030","first-page":"1733","article-title":"Permeability of human erythrocytes to asparagines","volume":"50","author":"Ataullakhanov","year":"1985","journal-title":"Biokhimiya"},{"issue":"4\u20135","key":"10.1016\/j.critrevonc.2015.01.002_bib0870","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.thromres.2003.10.007","article-title":"Thrombosis in children with acute lymphoblastic leukemia. Part II. Pathogenesis of thrombosis in children with acute lymphoblastic leukemia: effects of the disease and therapy","volume":"111","author":"Athale","year":"2003","journal-title":"Thromb Res"},{"issue":"4","key":"10.1016\/j.critrevonc.2015.01.002_bib0640","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2165\/00003088-200544040-00003","article-title":"Pharmacokinetic\/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future","volume":"44","author":"Avramis","year":"2005","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"10.1016\/j.critrevonc.2015.01.002_bib0650","first-page":"241","article-title":"Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia","volume":"1","author":"Avramis","year":"2006","journal-title":"Int J Nanomedicine"},{"issue":"6","key":"10.1016\/j.critrevonc.2015.01.002_bib0610","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1182\/blood.V99.6.1986","article-title":"A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study","volume":"99","author":"Avramis","year":"2002","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.critrevonc.2015.01.002_bib0760","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3109\/10428194.2010.537796","article-title":"Asparaginase revisited","volume":"52","author":"Berg","year":"2010","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.critrevonc.2015.01.002_bib0875","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000095827","article-title":"Fatal liver failure in an adult patient with acute lymphoblastic leukemia following treatment with L-asparaginase","volume":"74","author":"Bodmer","year":"2006","journal-title":"Digestion"},{"issue":"9","key":"10.1016\/j.critrevonc.2015.01.002_bib0680","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1016\/0959-8049(96)00131-1","article-title":"Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations","volume":"32A","author":"Boos","year":"1996","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.critrevonc.2015.01.002_bib0535","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1084\/jem.118.1.121","article-title":"Evidence that the L-asparaginase of guinea pig serum is responsible for its antilymphoma effects. II. Lymphoma 6C3HED cells cultured in a medium devoid of L-asparagine lose their susceptibility to the effects of guinea pig serum in vivo","volume":"118","author":"Broome","year":"1963","journal-title":"J Exp Med"},{"issue":"5","key":"10.1016\/j.critrevonc.2015.01.002_bib0960","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/j.2164-0947.1968.tb02511.x","article-title":"L-asparaginase: the evolution of a new tumor inhibitory agent","volume":"30","author":"Broome","year":"1968","journal-title":"Trans N Y Acad Sci"},{"issue":"5232","key":"10.1016\/j.critrevonc.2015.01.002_bib0990","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/225549a0","article-title":"Effect of L-asparaginase from Aspergillus terreus on ascites sarcoma in the rat","volume":"225","author":"Carta de-Angeli","year":"1970","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2015.01.002_bib0900","series-title":"Cancer chemotherapy and biotherapy, principle and practice (Vol. 2)","article-title":"Enzyme therapy: L-asparaginase","author":"Chabner","year":"1996"},{"issue":"4","key":"10.1016\/j.critrevonc.2015.01.002_bib0530","first-page":"369","article-title":"La D\u00e9samidation Enzymatique De L\u2019asparagine Chez Les Diff\u00e9rentes Esp\u00e9ces Animales Et La Signification Physio Logique De Sa Presence Dans L\u2019organisme","volume":"19","author":"Clementi","year":"1922","journal-title":"Arch Physiol Biochem"},{"key":"10.1016\/j.critrevonc.2015.01.002_bib0540","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/233485a0","article-title":"l-Asparaginase and complement","volume":"233","author":"Delage","year":"1971","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2015.01.002_bib1025","first-page":"514","article-title":"Isolation and characterization of L-asparaginase from marine actinomycetes","volume":"5","author":"Dhevagi","year":"2006","journal-title":"Ind J Biotechnol"},{"issue":"3","key":"10.1016\/j.critrevonc.2015.01.002_bib0600","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/ijc.2910300314","article-title":"Glutaminase-free asparaginase from vibrio succinogenes: an antilymphoma enzyme lacking hepatotoxicity","volume":"30","author":"Distasio","year":"1982","journal-title":"Int J Cancer"},{"issue":"12","key":"10.1016\/j.critrevonc.2015.01.002_bib0550","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1002\/1097-0142(196612)19:12<1813::AID-CNCR2820191208>3.0.CO;2-E","article-title":"Toxic and antineoplastic effects of L-asparaginase. Study of mice with lymphoma and normal monkeys and report on a child with leukemia","volume":"19","author":"Dolowy","year":"1966","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.critrevonc.2015.01.002_bib0775","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1182\/blood-2006-07-035006","article-title":"Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia","volume":"109","author":"Douer","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.01.002_bib0980","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0021-9258(18)91606-6","article-title":"The intracellular enzymes of lower fungi, especially those in Penicillium camemberti","volume":"6","author":"Dox","year":"1909","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.critrevonc.2015.01.002_bib0665","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s12088-011-0158-6","article-title":"L-asparaginase production by moderate halophilic bacteria isolated from Maharloo Salt Lake","volume":"51","author":"Ebrahiminezhad","year":"2012","journal-title":"Indian J Microbiol"},{"issue":"1","key":"10.1016\/j.critrevonc.2015.01.002_bib0880","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0163-7258(95)00012-6","article-title":"Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity","volume":"67","author":"Fromenty","year":"1995","journal-title":"Pharmacol Ther"},{"issue":"Suppl 2","key":"10.1016\/j.critrevonc.2015.01.002_bib0885","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0168-8278(97)80496-5","article-title":"Impaired mitochondrial function in microvesicular steatosis. Effects of drugs, ethanol, hormones and cytokines","volume":"26","author":"Fromenty","year":"1997","journal-title":"J Hepatol"},{"issue":"12","key":"10.1016\/j.critrevonc.2015.01.002_bib0745","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1517\/14656566.8.12.1977","article-title":"PEG-asparaginase","volume":"8","author":"Fu","year":"2007","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"10.1016\/j.critrevonc.2015.01.002_bib0560","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1517\/14728210903456026","article-title":"Emerging therapy for the treatment of acute lymphoblastic leukemia","volume":"15","author":"Fullmer","year":"2010","journal-title":"Expert Opin Emerg Drugs"},{"issue":"7","key":"10.1016\/j.critrevonc.2015.01.002_bib0710","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1093\/oxfordjournals.annonc.a010722","article-title":"L-asparagine depletion in plasma and cerebro-spinal fluid of children with acute lymphoblastic leukemia during subsequent exposures to Erwinia L-asparaginase","volume":"7","author":"Gentili","year":"1996","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.critrevonc.2015.01.002_bib1035","first-page":"10","volume":"1","author":"Godfrin","year":"2006","journal-title":"Oncology news"},{"issue":"10","key":"10.1016\/j.critrevonc.2015.01.002_bib0805","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0169-409X(03)00110-8","article-title":"Pegaspargase: a review of clinical studies","volume":"55","author":"Graham","year":"2003","journal-title":"Adv Drug Deliv Rev"},{"issue":"6","key":"10.1016\/j.critrevonc.2015.01.002_bib0770","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/sj.leu.2403351","article-title":"Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia","volume":"18","author":"Hak","year":"2004","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.critrevonc.2015.01.002_bib0740","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nrd1033","article-title":"Effect of pegylation on pharmaceuticals","volume":"2","author":"Harris","year":"2003","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.critrevonc.2015.01.002_bib0850","doi-asserted-by":"crossref","first-page":"142","DOI":"10.2353\/ajpath.2006.051238","article-title":"L-asparaginase-induced antithrombin type I deficiency: implications for conformational diseases","volume":"169","author":"Hernandez-Espinosa","year":"2006","journal-title":"Am J Pathol"},{"issue":"17","key":"10.1016\/j.critrevonc.2015.01.002_bib0955","doi-asserted-by":"crossref","first-page":"5375","DOI":"10.1016\/S0021-9258(17)33171-X","article-title":"Physical properties of antitumor glutaminase-asparaginase from Pseudomonas 7A","volume":"251","author":"Holcenberg","year":"1976","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1016\/j.critrevonc.2015.01.002_bib0795","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1177\/106002809703100517","article-title":"Pegaspargase: an alternative?","volume":"31","author":"Holle","year":"1997","journal-title":"Ann Pharmacother"},{"issue":"2","key":"10.1016\/j.critrevonc.2015.01.002_bib0930","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1182\/blood-2005-07-2930","article-title":"The expression of 70 apoptosis genes in relation to lineage, genetic subtype, cellular drug resistance, and outcome in childhood acute lymphoblastic leukemia","volume":"107","author":"Holleman","year":"2006","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.critrevonc.2015.01.002_bib0630","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1006\/bbrc.1999.0920","article-title":"L-asparaginase inhibits the rapamycin-targeted signaling pathway","volume":"260","author":"Iiboshi","year":"1999","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"10.1016\/j.critrevonc.2015.01.002_bib0910","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1172\/JCI30235","article-title":"Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase","volume":"117","author":"Iwamoto","year":"2007","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.critrevonc.2015.01.002_bib0635","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18632\/oncoscience.1","article-title":"Targeting glutamine uptake in AML","volume":"1","author":"Jacque","year":"2014","journal-title":"Oncoscience"},{"issue":"3","key":"10.1016\/j.critrevonc.2015.01.002_bib0920","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1182\/blood.V85.3.751.bloodjournal853751","article-title":"Favorable prognosis of hyperdiploid common acute lymphoblastic leukemia may be explained by sensitivity to antimetabolites and other drugs: results of an in vitro study","volume":"85","author":"Kaspers","year":"1995","journal-title":"Blood"},{"issue":"Suppl","key":"10.1016\/j.critrevonc.2015.01.002_bib0570","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3109\/10428199309149129","article-title":"L-asparaginase and PEG asparaginase \u2013 past, present, and future","volume":"10","author":"Keating","year":"1993","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.critrevonc.2015.01.002_bib1040","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/leu.2008.387","article-title":"Depletion of L-asparagine supply and apoptosis of leukemia cells induced by human glycosylasparaginase","volume":"23","author":"Kelo","year":"2009","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.critrevonc.2015.01.002_bib0525","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1084\/jem.98.6.565","article-title":"Regression of transplanted lymphomas induced in vivo by means of normal guinea pig serum. I. Course of transplanted cancers of various kinds in mice and rats given guinea pig serum, horse serum, or rabbit serum","volume":"98","author":"Kidd","year":"1953","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.critrevonc.2015.01.002_bib0575","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/1097-0142(197601)37:1<220::AID-CNCR2820370132>3.0.CO;2-W","article-title":"Hypersensitive reactions and antibody formation during L-asparaginase treatment of children and adults with acute leukemia","volume":"37","author":"Killander","year":"1976","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2015.01.002_bib0580","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1042\/BJ20061708","article-title":"Tailoring structure-function properties of L-asparaginase: engineering resistance to trypsin cleavage","volume":"404","author":"Kotzia","year":"2007","journal-title":"Biochem J"},{"issue":"5","key":"10.1016\/j.critrevonc.2015.01.002_bib0820","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/sj.leu.2401007","article-title":"Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia","volume":"12","author":"Larson","year":"1998","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.critrevonc.2015.01.002_bib0565","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF02922693","article-title":"L-asparaginase from Erwinia carotovora. An improved recovery and purification process using affinity chromatography","volume":"22","author":"Lee","year":"1989","journal-title":"Appl Biochem Biotechnol"},{"issue":"5","key":"10.1016\/j.critrevonc.2015.01.002_bib0965","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/0031-9422(92)83098-J","article-title":"L-asparaginase from developing seeds of Lupinus arboreus","volume":"31","author":"Lough","year":"1992","journal-title":"Phytochemistry"},{"key":"10.1016\/j.critrevonc.2015.01.002_bib1020","doi-asserted-by":"crossref","first-page":"138","DOI":"10.4236\/aim.2012.22019","article-title":"Purification and biochemical characterization of native and pegylated form of L-asparaginase from Aspergillus terreus and evaluation of Its ant proliferative activity","volume":"2","author":"Loureiro","year":"2012","journal-title":"Adv Microbiol"},{"key":"10.1016\/j.critrevonc.2015.01.002_bib0660","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.biortech.2012.08.086","article-title":"Efficient production of L-asparaginase from Bacillus licheniformis with low-glutaminse activity: Optimization, scale up and acrylamide degradation studies","volume":"125C","author":"Mahajan","year":"2012","journal-title":"Bioresour Technol"},{"key":"10.1016\/j.critrevonc.2015.01.002_bib0585","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/0003-9861(64)90032-3","article-title":"Tumor inhibitory effect of L-asparaginase from Escherichia coli","volume":"105","author":"Mashburn","year":"1964","journal-title":"Arch Biochem Biophys"},{"issue":"1","key":"10.1016\/j.critrevonc.2015.01.002_bib0790","first-page":"183","article-title":"Amino acid levels following L-asparagine amidohydrolase (EC.3.5.1.1) therapy","volume":"29","author":"Miller","year":"1969","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.critrevonc.2015.01.002_bib0860","first-page":"116","article-title":"Hemostatic changes in children with acute lymphoblastic leukemia treated according to two different L-asparaginase schedules","volume":"8","author":"Miniero","year":"1986","journal-title":"Am J Pediatr Hematol Oncol"},{"issue":"2","key":"10.1016\/j.critrevonc.2015.01.002_bib0855","first-page":"120","article-title":"Effect of disease and chemotherapy on hemostasis in children with acute lymphoid leukemia","volume":"16","author":"Mitchell","year":"1994","journal-title":"Am J Pediatr Hematol Oncol"},{"issue":"Pt 3","key":"10.1016\/j.critrevonc.2015.01.002_bib0590","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1042\/bj3020921","article-title":"Erwinia chrysanthemi L-asparaginase: epitope mapping and production of antigenically modified enzymes","volume":"302","author":"Moola","year":"1994","journal-title":"Biochem J"},{"issue":"2","key":"10.1016\/j.critrevonc.2015.01.002_bib0690","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S1040-8428(98)00015-8","article-title":"Use of L-asparaginase in childhood ALL","volume":"28","author":"Muller","year":"1998","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"10.1016\/j.critrevonc.2015.01.002_bib0865","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0049-3848(01)00286-9","article-title":"Thrombotic events revisited in children with acute lymphoblastic leukemia: impact of concomitant Escherichia coli asparaginase\/prednisone administration","volume":"103","author":"Nowak-Gottl","year":"2001","journal-title":"Thromb Res"},{"issue":"7","key":"10.1016\/j.critrevonc.2015.01.002_bib0840","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1182\/blood-2002-06-1901","article-title":"Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols): prednisone versus dexamethasone administration","volume":"101","author":"Nowak-Gottl","year":"2003","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.critrevonc.2015.01.002_bib0975","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1007\/s12010-009-8667-z","article-title":"Anticancer properties of highly purified L-asparaginase from Withania somnifera L. against acute lymphoblastic leukemia","volume":"160","author":"Oza","year":"2010","journal-title":"Appl Biochem Biotechnol"},{"issue":"4","key":"10.1016\/j.critrevonc.2015.01.002_bib0645","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/00043426-200404000-00002","article-title":"Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961","volume":"26","author":"Panosyan","year":"2004","journal-title":"J Pediatr Hematol Oncol"},{"issue":"3","key":"10.1016\/j.critrevonc.2015.01.002_bib0545","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ctrv.2010.08.002","article-title":"Asparaginase in the management of adult acute lymphoblastic leukaemia: is it used appropriately?","volume":"37","author":"Patil","year":"2011","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"10.1016\/j.critrevonc.2015.01.002_bib0950","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1042\/bj2030109","article-title":"Isolation and characterization of a Chlamydomonas L-asparaginase","volume":"203","author":"Paul","year":"1982","journal-title":"Biochem J"},{"issue":"11","key":"10.1016\/j.critrevonc.2015.01.002_bib0845","doi-asserted-by":"crossref","first-page":"664","DOI":"10.20452\/pamw.518","article-title":"Use of L-asparaginase in acute lymphoblastic leukemia: recommendations of the Polish Adult Leukemia Group","volume":"118","author":"Piatkowska-Jakubas","year":"2008","journal-title":"Pol Arch Med Wewn"},{"issue":"2","key":"10.1016\/j.critrevonc.2015.01.002_bib0670","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/cncr.25489","article-title":"L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase","volume":"117","author":"Pieters","year":"2010","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2015.01.002_bib0835","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/cncr.25489","article-title":"L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase","volume":"117","author":"Pieters","year":"2011","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2015.01.002_bib0895","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/bjh.12016","article-title":"Asparaginase-associated pancreatitis in children","volume":"159","author":"Raja","year":"2012","journal-title":"Br J Haematol"},{"issue":"11 Pt 1","key":"10.1016\/j.critrevonc.2015.01.002_bib0785","first-page":"4554","article-title":"L-asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans","volume":"41","author":"Riccardi","year":"1981","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.critrevonc.2015.01.002_bib0705","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1023\/A:1008368916800","article-title":"L-asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukemia receiving i.m. or i.v. Erwinia C. or E. coli L-asparaginase as first exposure","volume":"11","author":"Rizzari","year":"2000","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.critrevonc.2015.01.002_bib0890","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1055\/s-2003-42647","article-title":"Histopathological features of L-asparaginase-induced liver disease","volume":"23","author":"Sahoo","year":"2003","journal-title":"Semin Liver Dis"},{"issue":"10","key":"10.1016\/j.critrevonc.2015.01.002_bib0695","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1517\/14712598.2012.718327","article-title":"Erwinia asparaginase in pediatric acute lymphoblastic leukemia","volume":"12","author":"Salzer","year":"2012","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"10.1016\/j.critrevonc.2015.01.002_bib0995","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/0003-9861(71)90274-8","article-title":"Purification and properties of an L-asparaginase from Fusarium tricinctum","volume":"142","author":"Scheetz","year":"1971","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.critrevonc.2015.01.002_bib0985","first-page":"134","article-title":"Uber die fermentative Desamidierung durch Aspergillus niger","volume":"221","author":"Schmalfuss","year":"1930","journal-title":"Bio- chemische Zeitschrift"},{"issue":"7","key":"10.1016\/j.critrevonc.2015.01.002_bib0715","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1002\/pbc.22417","article-title":"Therapeutic drug monitoring of asparaginase in the ALL-BFM 2000 protocol between 2000 and 2007","volume":"54","author":"Schrey","year":"2010","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2015.01.002_bib1010","first-page":"104","article-title":"Biotechnological advancement in isolation of anti-neoplastic compounds from natural origin: a novel source of L-asparaginase","volume":"81","author":"Shrivastava","year":"2010","journal-title":"Acta Biomed"},{"issue":"6","key":"10.1016\/j.critrevonc.2015.01.002_bib1015","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1080\/10826068.2012.672943","article-title":"Kinetic studies of L-asparaginase from Penicillium digitatum","volume":"42","author":"Shrivastava","year":"2012","journal-title":"Prep Biochem Biotech"},{"issue":"1-2","key":"10.1016\/j.critrevonc.2015.01.002_bib0595","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0378-5173(02)00046-7","article-title":"Effects of polyethylene glycol attachment on physicochemical and biological stability of E. coli L-asparaginase","volume":"237","author":"Soares","year":"2002","journal-title":"Int J Pharm"},{"issue":"1","key":"10.1016\/j.critrevonc.2015.01.002_bib0970","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1104\/pp.65.1.22","article-title":"Distribution and properties of a potassium-dependent Asparaginase isolated from developing seeds of Pisum sativum and other plants","volume":"65","author":"Sodek","year":"1980","journal-title":"Plant Physiol"},{"issue":"11","key":"10.1016\/j.critrevonc.2015.01.002_bib0925","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1182\/blood-2004-10-3892","article-title":"Asparagine synthetase expression is linked with L-asparaginase resistance in TEL-AML1-negative but not TEL-AML1-positive pediatric acute lymphoblastic leukemia","volume":"105","author":"Stams","year":"2005","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.critrevonc.2015.01.002_bib0555","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1073\/pnas.90.4.1474","article-title":"Crystal structure of Escherichia coli L-asparaginase, an enzyme used in cancer therapy","volume":"90","author":"Swain","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.critrevonc.2015.01.002_bib0905","article-title":"L-Asparaginase, nitric oxide and posterior reversible encephalopathy syndrome","author":"Thachil","year":"2012","journal-title":"Ann Hematol"},{"issue":"9","key":"10.1016\/j.critrevonc.2015.01.002_bib0935","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1684\/bdc.2010.1168","article-title":"Therapeutic alternatives to native L-asparaginase in the treatment of adult acute lymphoblastic leukemia","volume":"97","author":"Thomas","year":"2010","journal-title":"Bull Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2015.01.002_bib0655","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/07388550601173926","article-title":"L-asparaginase: a promising chemotherapeutic agent","volume":"27","author":"Verma","year":"2007","journal-title":"Crit Rev Biotechnol"},{"issue":"5","key":"10.1016\/j.critrevonc.2015.01.002_bib0730","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S0142-9612(00)00193-9","article-title":"Peptide and protein PEGylation: a review of problems and solutions","volume":"22","author":"Veronese","year":"2001","journal-title":"Biomaterials"},{"issue":"21","key":"10.1016\/j.critrevonc.2015.01.002_bib0735","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S1359-6446(05)03575-0","article-title":"PEGylation, successful approach to drug delivery","volume":"10","author":"Veronese","year":"2005","journal-title":"Drug Discov Today"},{"issue":"1","key":"10.1016\/j.critrevonc.2015.01.002_bib0750","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1046\/j.1365-2141.2001.02680.x","article-title":"Drug monitoring of low-dose PEG-asparaginase (Oncaspar) in children with relapsed acute lymphoblastic leukaemia","volume":"113","author":"Vieira Pinheiro","year":"2001","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.critrevonc.2015.01.002_bib0765","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/pbc.20406","article-title":"Serum asparaginase activities and asparagine concentrations in the cerebrospinal fluid after a single infusion of 2,500 IU\/m(2) PEG asparaginase in children with ALL treated according to protocol COALL-06-97","volume":"46","author":"Vieira Pinheiro","year":"2006","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2015.01.002_bib0605","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0378-4274(86)90113-X","article-title":"L-asparaginase effects on inhibition of protein synthesis and lowering of the glutamine content in cultured rat hepatocytes","volume":"32","author":"Villa","year":"1986","journal-title":"Toxicol Lett"},{"key":"10.1016\/j.critrevonc.2015.01.002_bib0755","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1749-6632.1990.tb18151.x","article-title":"Antitumor enzyme: polyethylene glycol-modified asparaginase","volume":"613","author":"Wada","year":"1990","journal-title":"Ann N Y Acad Sci"},{"issue":"8","key":"10.1016\/j.critrevonc.2015.01.002_bib0830","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1038\/sj.leu.2403011","article-title":"Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients","volume":"17","author":"Wang","year":"2003","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.critrevonc.2015.01.002_bib0815","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1055\/s-2005-872516","article-title":"asparagine concentration in plasma after 2,500 IU\/m(2) PEG-asparaginase i.v. in children with acute lymphoblastic leukemia","volume":"217","author":"Wenner","year":"2005","journal-title":"Klin Padiatr"},{"issue":"1","key":"10.1016\/j.critrevonc.2015.01.002_bib0915","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1056\/NEJMcibr072412","article-title":"A new mechanism of leukemia drug resistance?","volume":"357","author":"Williams","year":"2007","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.critrevonc.2015.01.002_bib0625","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.tibs.2010.05.003","article-title":"glutamine addiction: a new therapeutic target in cancer","volume":"35","author":"Wise","year":"2010","journal-title":"Trends Biochem Sci"},{"issue":"7","key":"10.1016\/j.critrevonc.2015.01.002_bib0825","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1200\/JCO.2000.18.7.1525","article-title":"Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia","volume":"18","author":"Woo","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2015.01.002_bib0945","first-page":"185","article-title":"L-asparaginase: a review","volume":"39","author":"Wriston","year":"1973","journal-title":"Adv Enzymol Relat Areas Mol Biol"},{"issue":"6","key":"10.1016\/j.critrevonc.2015.01.002_bib0620","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/ijc.2910220615","article-title":"Mechanism of sensitivity of cultured pancreatic carcinoma to asparaginase","volume":"22","author":"Wu","year":"1978","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2015.01.002_bib0615","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1517\/14712590802586058","article-title":"Pegasparaginase: where do we stand?","volume":"9","author":"Zeidan","year":"2009","journal-title":"Expert Opin Biol Ther"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842815000037?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842815000037?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T14:00:47Z","timestamp":1747404047000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842815000037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":104,"alternative-id":["S1040842815000037"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2015.01.002","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent developments in l-asparaginase discovery and its potential as anticancer agent","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2015.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}